On June 10, Insilico Medicine fell 5.09% in regular trading, trading at HK$31.88/share, with trading volume of HK$30.32 million.

On the news front, the company's cornerstone investors and employee restricted shares are set to exit their lock-up period on June 29, with approximately 453 million shares facing potential release — representing 81.25% of total share capital. Market concerns over concentrated selling pressure continue to intensify. The stock has declined nearly 40% over the past month, falling from its April highs.

Fundamentally, the company reported revenue of US$56.24 million for 2025, a year-over-year decline of 34.48%, with net loss attributable to shareholders reaching US$352 million. The current share price still carries a premium over its IPO price, meaning original shareholders remain in profit and have incentive to reduce holdings upon unlock.

Within the Life Sciences Tools and Services sector, the broader group also traded lower. WuXi Biologics fell 2.87%, GenScript Biotech declined 3.03%, and WuXi XDC dropped 3.14%, with sector-wide weakness further dampening sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)